Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | RIPK1 | Q13546 | 3/20 | 0.42 |
| ▸ | PAK1 | Q13153 | 2/20 | 0.40 |
| ▸ | METAP2 | P50579 | 1/20 | 0.38 |
| ▸ | METAP1 | P53582 | 1/20 | 0.38 |
| ▸ | HPGDS | O60760 | 1/20 | 0.37 |
| ▸ | CDC7 | O00311 | 5/20 | 0.37 |
| ▸ | DBF4 | Q9UBU7 | 5/20 | 0.37 |
| ▸ | PIM1 | P11309 | 2/20 | 0.36 |
| ▸ | MAPK1 | P28482 | 2/20 | 0.36 |
| ▸ | DYRK3 | O43781 | 1/20 | 0.36 |
| ▸ | ROCK2 | O75116 | 1/20 | 0.36 |
| ▸ | MAP4K4 | O95819 | 1/20 | 0.36 |
| ▸ | CDK1 | P06493 | 1/20 | 0.36 |
| ▸ | CSF1R | P07333 | 1/20 | 0.36 |
| ▸ | PRKACA | P17612 | 1/20 | 0.36 |
| ▸ | CDK2 | P24941 | 1/20 | 0.36 |
| ▸ | MARK3 | P27448 | 1/20 | 0.36 |
| ▸ | CSNK1A1 | P48729 | 1/20 | 0.36 |
| ▸ | CSNK1D | P48730 | 1/20 | 0.36 |
| ▸ | CLK2 | P49760 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL15264146 | 0.95 | RIPK1 (0.47) | RIPK1PAK1METAP2METAP1HPGDS | |
| SCHEMBL2789821 | 0.94 | METAP2 (0.40) | RIPK1PAK1METAP2METAP1HPGDS | |
| SCHEMBL16145856 | 0.83 | LATS1 (0.36) | METAP2METAP1PIM1KDM4EALDH1A1 | |
| SCHEMBL16145858 | 0.75 | RIPK1 (0.44) | RIPK1PAK1HPGDSCDC7DBF4 | |
| SCHEMBL7662481 | 0.74 | RIPK1 (0.46) | RIPK1PAK1HPGDSCDC7DBF4 | |
| SCHEMBL5072700 | 0.74 | METAP2 (0.44) | METAP2METAP1CSNK2A1EGFR | |
| SCHEMBL3421963 | 0.74 | METAP2 (0.44) | METAP2METAP1 | |
| SCHEMBL9356684 | 0.74 | METAP2 (0.44) | METAP2METAP1 | |
| SCHEMBL5828208 | 0.74 | METAP2 (0.44) | METAP2METAP1LMNAKDM4EALDH1A1 | |
| SCHEMBL3426596 | 0.73 | METAP2 (0.41) | METAP2METAP1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2313422-B1 | NUCLEOSIDE CYCLICPHOSPHATES | GILEAD PHARMASSET LLC (US) | 2015-03-04 | — | — | EP | disclosed |
| US-8759510-B2 | Nucleoside cyclicphosphates | GILEAD PHARMASSET LLC (US) | 2014-06-24 | — | — | US | disclosed |
| US-20120258928-A1 | NUCLEOSIDE CYCLICPHOSPHATES | GILEAD PHARMASSET LLC (US) | 2012-10-11 | — | — | US | disclosed |
| US-8173621-B2 | Nucleoside cyclicphosphates | GILEAD PHARMASSET LLC (US) | 2012-05-08 | — | — | US | disclosed |
| CN-102119167-A | nucleoside cyclic phosphates | PHARMASSET INC | 2011-07-06 | — | — | CN | disclosed |
| EP-2313422-A2 | NUCLEOSIDE CYCLICPHOSPHATES | Pharmasset, Inc. (US) | 2011-04-27 | — | — | EP | disclosed |
| US-20100081628-A1 | NUCLEOSIDE CYCLICPHOSPHATES | PHARMASSET, INC. (US) | 2010-04-01 | — | — | US | disclosed |
| WO-2009152095-A2 | NUCLEOSIDE CYCLICPHOSPHATES | PHARMASSET, INC. (US) | 2009-12-17 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120258928-A1 | NUCLEOSIDE CYCLICPHOSPHATES | PNP, NUDT1, TYMP | RIPK1 3072/4885PAK1 1694/4885METAP2 844/4885 |
| US-20100081628-A1 | NUCLEOSIDE CYCLICPHOSPHATES | PNP, NUDT1, TYMP | RIPK1 3072/4885PAK1 1694/4885METAP2 844/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.